|
|
 |
TRIACETIN Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
UBRELVY Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
TROMETHAMINE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
VEKLURY Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
VEMLIDY Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|